Workshop Report: Crystal City VI-Bioanalytical Method Validation for Biomarkers

Area of Science:

• Biomarker research
• Pharmaceutical industry
• Translational research

Background:

• Biomarker assays, crucial for drug development, historically lacked standardized validation and performance expectations.
• This led to inconsistent data quality submitted to regulatory agencies like the US Food and Drug Administration (FDA).
• The absence of clear standards impacted the reliability of biomarker data supporting efficacy and safety claims.

Framework:

• The US Food and Drug Administration's (FDA) 2013 draft guidance on bioanalytical method validation addressed biomarker assays (LC-MS, LBA).
• This guidance marked a shift towards establishing performance standards for biomarker measurements.
• It aimed to standardize the quality of data used in drug development.

Implementation:

• The 2015 AAPS Crystal City VI (CC VI) Workshop convened industry and FDA representatives.
• This workshop served as a primary forum for discussing challenges in biomarker measurement, including endogenous levels.
• It facilitated discussions on the strengths and weaknesses of various assay technologies.

Implications:

• The CC VI Workshop fostered a shared understanding of biomarker measurement issues within the scientific community.
• It informed the FDA about the current state of biomarker assay science.
• The workshop established a foundation for ongoing dialogue and future advancements in biomarker assay validation and application.